Johnson & Johnson's (JNJ -0.69%) med device segment had a pretty sleepy first quarter, with 0.7% revenue growth (about 1% operationally). But management highlighted some new and exciting opportunities for this underloved division, including a huge potential tailwind from the Affordable Care Act (also known as Obamacare). Watch the video below for more on this exciting growth opportunity.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.